When will retatrutide be approved? What the new trial data shows

Retatrutide is the weight-loss drug people keep asking about before they can actually get it. Eli Lilly released results from two more Phase 3 trials on 23 July 2026, and they answer a question the headline numbers never did: how well does this triple agonist work in people who already have type 2 diabetes or established heart disease? Here is what the data shows, and when a prescription becomes realistic.

TL;DR

Retatrutide produced 20.8% average weight loss over 80 weeks in adults with type 2 diabetes and 22.6% in adults with severe obesity plus established cardiovascular disease. Lilly plans to file with the FDA in the first quarter of 2027, which puts a realistic approval in late 2027 at the earliest and more likely 2028.

What retatrutide is, in plain terms

Most GLP-1 medications you know work on one hormone receptor. Semaglutide, the ingredient in Ozempic and Wegovy, hits the GLP-1 receptor. Tirzepatide, in Mounjaro and Zepbound, hits two: GLP-1 and GIP. Retatrutide hits three. It adds the glucagon receptor on top of GLP-1 and GIP, which is why people call it the triple-G drug.

That third receptor is the interesting one. GLP-1 and GIP mostly reduce how much you eat. Glucagon works from the other side of the equation, pushing the liver to mobilise stored fat and nudging energy expenditure upward. In theory, you get appetite suppression and a metabolic push at the same time. The trade-off researchers watched for was blood sugar, since glucagon normally raises glucose. In the diabetes trial, that concern did not materialise.

TRIUMPH-2: what happened in people with type 2 diabetes

Weight loss is usually harder in type 2 diabetes. Every drug in this class delivers a few percentage points less in diabetic patients than in people without diabetes, and that pattern has held for semaglutide and tirzepatide alike. So the TRIUMPH-2 numbers matter more than a raw percentage suggests.

The trial randomised 1,152 adults with type 2 diabetes and overweight or obesity to retatrutide at 4 mg, 9 mg or 12 mg, or to placebo, for 80 weeks. Average starting weight was 106.4 kg (234.6 lb) with a BMI of 38.2.

Average weight loss at 80 weeks:

• Retatrutide 4 mg: 12.7%, or about 29.8 lb
• Retatrutide 9 mg: 19.1%, or about 45.4 lb
• Retatrutide 12 mg: 20.8%, or about 49.6 lb
• Placebo: 4.0%, or about 9.3 lb

Blood sugar moved too. Starting from an average A1C of 7.7%, the three doses cut it by 1.4, 1.6 and 1.5 percentage points respectively, against 0.2 on placebo. Note that the middle dose matched or beat the top dose on glycemic control while delivering less weight loss, which suggests the two effects do not scale together in lockstep.

TRIUMPH-3: severe obesity plus established heart disease

This trial enrolled a harder population: 1,949 adults with severe obesity and diagnosed cardiovascular disease, average weight 111.4 kg (245.6 lb) and BMI 40.4. They received 9 mg, 12 mg or placebo over the same 80 weeks.

Average weight loss was 21.6% on 9 mg (about 52.7 lb) and 22.6% on 12 mg (about 55.8 lb), against 3.2% on placebo. At the top dose, the cardiometabolic markers moved sharply as well: triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, waist circumference down 7.5 inches (19.0 cm), and high-sensitivity C-reactive protein, a marker of inflammation, down 51.2%.

Here is where honesty matters. The trial also counted actual cardiovascular events, and those numbers were not conclusive. For the broader five-component endpoint, retatrutide showed a hazard ratio of 0.82 with a 95% confidence interval of 0.55 to 1.22, meaning 44 events on the drug versus 52 on placebo. For the narrower three-component endpoint, the hazard ratio was 1.12 (95% CI 0.64 to 1.96), with 27 events versus 23. Both intervals cross 1.0, so neither result proves benefit or harm. This trial was not designed as a dedicated cardiovascular outcomes study, and a proper answer on heart events will need one.

So when will retatrutide actually be approved?

Lilly says it will submit a Biologics License Application to the FDA in the first quarter of 2027. That is the concrete date, and everything else is arithmetic on top of it.

Standard FDA review runs roughly ten months from filing. Priority review, which obesity drugs do not automatically receive, runs about six. If the filing lands on schedule in early 2027 and review runs to type, the earliest plausible approval is late 2027, and 2028 is the more realistic bet once you account for the usual back-and-forth on manufacturing and labelling. Anyone promising you a 2026 launch is guessing.

What strengthens the case is volume of evidence. Retatrutide now has five positive Phase 3 studies behind it. The wider TRIUMPH programme enrolled more than 5,800 participants across four global registrational trials that began in 2023, covering obesity, moderate-to-severe obstructive sleep apnea with obesity, and knee osteoarthritis pain. Kenneth Custer, who leads Lilly's cardiometabolic health division, described retatrutide as a potential "important future tool" in cardiometabolic management. Company language, so weigh it accordingly, but the underlying data package is genuinely deep.

One warning. Retatrutide is not approved anywhere, which means anything sold online under that name today is unregulated. Sellers marketing it as a research chemical operate outside pharmaceutical manufacturing standards, with no verification of what is in the vial, what dose it contains, or whether it is sterile. This is a different situation from compounded semaglutide, which at least copies an approved molecule. There is no legitimate consumer supply of retatrutide right now.

How it compares with what you can get today

Retatrutide's flagship result came from TRIUMPH-1, reported in May 2026: 28.3% average weight loss at the 12 mg dose over 80 weeks, and up to 30.3% at 104 weeks among participants who started with a BMI of 35 or higher and stayed on treatment. That is bariatric-surgery territory.

For context on approved options, the SURMOUNT-5 head-to-head trial put tirzepatide at 20.2% and semaglutide at 13.7% over 72 weeks in adults with obesity and without diabetes. You can read our full breakdown of how tirzepatide and semaglutide compared in SURMOUNT-5.

Resist the urge to line those percentages up as a ranking. TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and SURMOUNT-5 used different populations, different durations and different comparators, and cross-trial comparison consistently flatters the newer drug. Retatrutide has never been tested directly against tirzepatide. Until it is, the fair statement is that retatrutide looks stronger on weight loss than anything currently approved, and that no one has proven it in a head-to-head.

The side effects worth knowing about now

The tolerability profile looks like the rest of the class, with the gastrointestinal effects sitting at the higher end. In TRIUMPH-2, comparing the 12 mg dose against placebo:

• Diarrhea: 33.6% versus 13.2%
• Nausea: 28.0% versus 8.0%
• Decreased appetite: 17.1% versus 4.5%
• Constipation: 16.8% versus 9.4%
• Vomiting: 15.7% versus 4.2%
• Dysesthesia: 7.3% versus 0.7%

That last one is less familiar. Dysesthesia means altered or uncomfortable skin sensation, often described as tingling, prickling or burning. It showed up roughly ten times more often on retatrutide than placebo, and it is worth watching as the programme matures.

Discontinuation tells you how liveable the drug was in practice. In TRIUMPH-2, 7.7% of the 12 mg group stopped because of side effects, against 4.9% on placebo. In the sicker TRIUMPH-3 population, 13.5% of the 12 mg group stopped, against 4.8% on placebo. Higher than placebo, and in line with what people already experience on high-dose tirzepatide.

What 20% plus weight loss means for your nutrition

Deeper weight loss is not a free upgrade. The appetite suppression that drives a 50 lb result also means eating substantially less food, for 80 weeks or longer, and food is where your micronutrients come from. Around a third of weight lost on GLP-1 medications is typically lean mass rather than fat, and the arithmetic gets less forgiving as the total climbs.

None of this is a reason to avoid these drugs. It is a reason to plan around them. Whether you are on Ozempic or Wegovy today or watching retatrutide for 2028, the nutritional groundwork is identical:

• Protein first, at roughly 1.2 to 1.6 g per kg of body weight per day, spread across meals rather than loaded into one
• Resistance training two or three times a week, which does more to protect muscle than any supplement
• Vitamin B12, which drops when total food intake falls and shows up as fatigue and brain fog
• Vitamin D and magnesium, both commonly low before treatment starts and easily missed once portions shrink
• Iron, especially for menstruating women, since low ferritin drives fatigue and hair shedding
• Omega-3 fats and zinc, which are hard to reach from small portions of food alone

Nutrient deficiency on GLP-1 medications is not hypothetical. Roughly one in three patients picks up a nutritional deficiency diagnosis within twelve months of starting, and most were never tested beforehand. Closing that gap is exactly what GLP-1 Shield is built for: the specific nutrients that drain away when a medication cuts your intake, in the amounts the research points to, so the muscle, hair and energy you are trying to keep are not quietly funded out of your reserves.

Frequently asked questions

When will retatrutide be available by prescription?

Lilly plans to submit its application to the FDA in the first quarter of 2027. With a standard review taking around ten months, the earliest realistic approval is late 2027, and 2028 is more likely once manufacturing and labelling steps are factored in. No approval is guaranteed until the FDA rules.

How much weight can you lose on retatrutide?

In the Phase 3 trials reported so far, average loss at the 12 mg dose was 28.3% in adults with obesity, 20.8% in adults with type 2 diabetes, and 22.6% in adults with severe obesity and heart disease, all over 80 weeks. Individual results vary widely, and these are averages from trial conditions with structured support.

Is retatrutide better than Zepbound or Wegovy?

On weight loss, the trial numbers are higher than anything approved today. But retatrutide has never been compared directly against tirzepatide or semaglutide in a head-to-head trial, and comparing across separate trials with different populations is unreliable. The honest answer is that it looks stronger and has not yet been proven stronger.

Can I buy retatrutide now?

Not legitimately. It is not approved in any country, so there is no licensed supply. Vials sold online as research chemicals are made outside pharmaceutical quality standards, with no assurance of dose, purity or sterility. Talk to your prescriber about approved options instead of sourcing an unapproved peptide.